Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLCu2O nanoparticles
- Development stage
- Preclinical
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
SLCu2O nanoparticles are copper oxide nanoparticles that have been green-synthesized using an extract from *S. latifolium* algae. These nanoparticles have demonstrated anti-cancer properties against PANC-1 cells, a human pancreatic cancer cell line. Their mechanism of action involves inducing apoptosis and up-regulating drug resistance-related long non-coding RNAs (lncRNAs), with effects comparable to Arsenic trioxide.
- Other names
- SLCu2O NPsSLCu-2O NPsSLCu 2O NPs
Beyond the preview
Go deeper on SLCu2O nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLCu2O nanoparticles.